Subject Index

Adenosine, mast cell activation modulation 60
Age, anaphylaxis risk factor 17, 18
Allergen
  anaphylaxis elicitors 9, 10
  insects, see Insect venom-induced anaphylaxis
  microarrays for anaphylaxis diagnosis 136
overview of characteristics 23
recognition by immune system
dendritic cell
  subsets 26
  T-cell interactions 26–28
immunoglobulin E suppression by interleukin-10 and Tregs 36
pathogen-associated molecular patterns 23–25
T cell
  activation signals 28, 29
  allergen-specific immunotherapy 34
B-cell interactions 35, 36
late-phase reactions 36, 37
subsets 29–34
Treg suppression of effector cells 34, 35
Allergy, see also specific allergies
diagnosis after anaphylaxis 9
Analgesics, see Nonsteroidal anti-inflammatory drugs
Anesthesia-induced anaphylaxis
  allergic reaction investigation
    histamine 187
    skin tests 187
    tryptase 187
causal agents
  local anesthetics 185, 186
  neuromuscular blocking agents 183–185
  non-immune-mediated hypersensitivity reactions 185, 186
  clinical features 185, 186
  epidemiology 181
local anesthetics
  clinical features 192
diagnosis
  history 197
  in vitro testing 197
  provocation testing 197
  skin testing 194, 195
hypersensitivity reactions
  contact allergy 193, 194
  immunoglobulin-E-mediated anaphylaxis 193
  pseudo-allergic reactions 194
overview 190, 191
pharmacologic effects 193
psychosomatic involvement 195, 196
reverse placebo provocation 196, 197
structures 191, 192
toxicity 193
overview 180, 181
susceptible populations 183
Angioedema, see also C1 inhibitor deficiency
angiotensin-converting enzyme inhibitor induction 79
rare hereditary forms 79
Angiotensin-converting enzyme inhibitors
angiotensin induction 80
angioedema induction 79
Anisakis extract, anaphylaxis induction and diagnosis 133
Antigen-presenting cell, see also Dendritic cell allergen recognition 24
Antihistamines, anaphylaxis management 205
Aprotinin, hypersensitivity 186
Aspirin, see Nonsteroidal anti-inflammatory drugs
Asthma, aspirin-induced
  clinical features 174
  diagnosis 173, 174
  prevention and treatment 175, 176
Atopy, anaphylaxis risk factor 18
Atropine, anaphylaxis management 206

Basophil
  anaphylaxis role
    alternative pathway without mast cells and immunoglobulin E 90, 91
    human studies 94
    immunoglobulin-G-mediated systemic anaphylaxis 91–94
    platelet-activating factor release 93, 94
    cutaneous basophil hypersensitivity 86
    cytokine production 87
    humoral memory response enhancement 88
    immunoglobulin-E-mediated chronic allergic inflammation initiation 88, 89
    markers 86
    mast cell similarities 85, 86
    Th2 cell differentiation role 87, 88
Basophil activation test, anaphylaxis diagnosis 128, 129, 133
B-cell, T-cell interactions and immunoglobulin E production 35, 36
Biphasic anaphylactic reaction, epidemiology 17
Bradykinin
  anaphylaxis role 79, 80
  C1 inhibitor deficiency, see C1 inhibitor deficiency
  cell surface assembly of plasma kinin-forming cascade 72, 73
  contact activation in formation 70–72
  diseases 67
  endothelial cells and kinin formation 73
  processing and degradation 68–70
C1 inhibitor deficiency
  acquired deficiency 77, 78
  angioedema 73, 74
  causes and heredity 74, 75
  diagnosis 76
  molecular genetics 75
  pathogenesis 76, 77
  treatment 78, 79
Calcium flux, FceRI signaling 52, 53
Carboxypeptidase A3, anaphylaxis diagnosis 128
Cardiac manifestations
  anaphylaxis 98, 99
  histamine H1 receptor activation and coronary hemodynamics 104, 105
  histamine infusion effects on cardiovascular system 103, 104
  leukotrienes and hemodynamic effects 105
Cardiac mast cell, see Mast cell
Chlorhexidine
  anaphylaxis induction and diagnosis 132
  hypersensitivity 185
Chymase, anaphylaxis diagnosis 127, 128
Complement, see also C1 inhibitor deficiency
  heart mast cell activation 102
  mast cell activation modulation 61
Cutaneous mastocytosis, see Mastocytosis

Dendritic cell
  functional overview 23
  pattern recognition receptors 24
  subsets 26
  T cell interactions 26–28
  polarization 25, 26
Differential diagnosis, anaphylactic reactions 8
Drug allergy, anaphylaxis diagnosis
  β-lactam antibiotics 129
  neuromuscular blocking agents 129–131
  nonsteroidal anti-inflammatory drugs 131, 132
  epidemiology 15, 16
Dyes, hypersensitivity 186
Ecallantide, C1 inhibitor deficiency management 78
Education, anaphylaxis risk patients 219
Endothelial cell, kinin formation 73
Epidemiology, anaphylaxis
  biphasic anaphylactic reaction 17
  data sources 12, 13
  drug allergy 15, 16
  food allergy 13–15
  limitations of study 13
  risk factors
    age 17, 18
    atopy 18

Subject Index
Epidemiology, anaphylaxis (continued)
- geography 18
- predisposing factors 17
- sex differences 18, 19
- socioeconomic status 19
- sting-induced anaphylaxis 16, 17

Epinephrine, anaphylaxis management
- dosing
- autoinjector 215–217
- incorrect injection 217, 218
- intramuscular 214, 215
- intravenous 215, 217
- number of doses 216
- emergency action plan 218, 219
- evidence for use 213, 214
- overview 202–204, 211
- pharmacologic activity 212, 213
- prospects for study 219, 220
- response 218
- stability of solutions 217
- therapeutic window 213

Factor XII, bradykinin formation 69
- FcεRI
  - binding affinity 48, 49
  - modulators of mast cell activation
    - adenosine 60
    - complement 61
    - immunoglobulin E enhancement of receptor expression 57, 58
    - stem cell factor 59, 60
    - variability in response 58, 59
  - signaling in immunoglobulin-E-dependent anaphylaxis
    - calcium flux 52, 53
    - membrane fusion events 53, 54
    - negative regulators 54–57
    - overview 49, 50
    - proximal signaling events 50–52

Fluid therapy, anaphylaxis management 205, 206

Food allergy, anaphylaxis
- diagnosis 134–136
- epidemiology 13–15

Gelatin, hypersensitivity 186

General anesthesia, see Anesthesia-induced anaphylaxis

Geographic distribution, anaphylaxis risk factors 18

Glucagon, anaphylaxis management 206

Glucocorticosteroids, anaphylaxis management 204, 205

Grading, anaphylaxis 7

Heart mast cell, see Mast cell

Hereditary angioedema, see C1 inhibitor deficiency

High molecular weight kininogen, bradykinin formation 70–72

Histamine
- anaphylaxis diagnosis 126, 187
- cardiovascular effects of infusion 103, 104
- receptor antagonists in anaphylaxis management 205
- synthesis, see Mast cell

Historical perspective, anaphylaxis 2–4

Hypnotics, hypersensitivity 185

Icatibant, C1 inhibitor deficiency management 78

Immunoglobulin E
- anaphylaxis modulation 4
- assays 136
- basophils and chronic allergic inflammation initiation 88, 89
- B-cell/T-cell interactions and production 35, 36
- receptor, see FcεRI
- suppression by interleukin-10 and Tregs 36

Immunoglobulin G
- assays 136
- immune complex reaction 4, 5
- mediated systemic anaphylaxis and basophils 91–94

Immunotherapy
- allergen-specific immunotherapy 34
- venom immunotherapy	extit{ efficacy and safety }151–153
- indications 153, 154
- protocols and duration 154

Insect venom-induced anaphylaxis
- allergens
  - ants 147
  - bees 146
  - overview 145, 146
  - recombinant allergens 147, 148
  - wasps and hornets 146, 147
- clinical presentation 148
- diagnosis
  - history 149, 150
  - overview 13, 134
skin tests 150, 151
sting provocation tests 151
epidemiology 16, 17, 148, 149
immunotherapy
efficacy and safety 151–153
indications 153, 154
protocols and duration 154
insect taxonomy and biology
ants 144
bees 142
overview 141, 142
wasps and hornets 143, 144
natural history 149, 150
prevention 151
Interleukin-10, immunoglobulin E suppression 36
c-kit
mastocytosis mutations 111, 112
mutant mice 46, 48
β-Lactam antibiotics, anaphylaxis induction and diagnosis 129, 185
Latex
allergy 185
anaphylaxis induction and diagnosis 133
Leukotrienes
heart mast cell synthesis 101
hemodynamic effects 105
Mast cell
heart mast cell
activation 102, 103
anaphylaxis role 103
cytokine synthesis 101, 102
histamine synthesis 99, 100
histology 99, 100
isolation 99
leukotrienes
hemodynamic effects 105
synthesis 101
prostaglandin D2 synthesis 101
protease synthesis 100
renin expression 100, 101
immunoglobulin E receptor, see FceRI
mouse/human differences 47
prospects for study 62, 63
secretory stages 5
Mastocytosis
anaphylaxis
clinical features 116, 117
elicitors 117, 118
susceptibility 110, 116
treatment 116, 117
clinical features
cutaneous involvement 112, 113
mast cell mediator-induced symptoms 115, 116
World Health Organization classification of systemic involvement 113–115
diagnosis 114, 118, 119
epidemiology 111
management
aggressive mastocytosis 122
avoidance of triggers 120, 121
mast cell mediator-induced symptoms 121
skin lesions 121, 122
pathogenesis 111, 112
Medical identification, anaphylaxis risk patients 219
Modular antigen translocation, vaccines 27
Mortality, anaphylaxis 8, 149
Mouse models, anaphylaxis
human mast cell differences 47
overview 46, 48, 49
Münchausen's syndrome 10
Neuromuscular blocking agents, anaphylaxis induction and diagnosis 129–131, 184, 185
Nonsteroidal anti-inflammatory drugs, hypersensitivity
allergic anaphylactic reactions 177
anaphylaxis induction and diagnosis 131, 132
aspirin adverse reactions
asthma
clinical features 174
diagnosis 173, 174
prevention and treatment 175, 176
cross-reactions with other analgesics 174, 175
overview 173
urticaria/angioedema 176
chemical classification 172
history of study 170–173
pyrazolones 176, 177
structures 171
Opioids, hypersensitivity 185
Pathogen-associated molecular patterns, allergens 24, 25
Platelet-activating factor
  anaphylaxis diagnosis 128
  basophil release in immunoglobulin-G-mediated systemic anaphylaxis 93, 94
Prekallikrein, bradykinin formation 69, 70
Protamine, hypersensitivity 186

Radiocontrast media hypersensitivity
  classification of adverse reactions 158, 159
  clinical presentation 159, 160
  diagnosis
    immediate reactions 165
    non-immediate reactions 166
  frequency 157, 158
  pathophysiology
    immediate reactions 160–163
    non-immediate reactions 163–165
  prevention 167
Regulatory T cell, see T cell
Reverse placebo provocation 196, 197

Sex differences, anaphylaxis risk factor 18, 19
Skin testing
  anesthesia-induced hypersensitivity
diagnosis 194, 195
  insect venom 150, 151
Socioeconomic status, anaphylaxis risk factor 19
Stem cell factor
  mast cell activation modulation 59, 60
  receptor, see c-kit

Symptoms, anaphylaxis
  anaphylaxis classification by severity 7
  differential diagnosis of reactions 8
  elicitors 9, 10
  overview 7
  prevalence by type 6

T cell
  activation signals 28, 29
  allergen-specific immunotherapy 34
  B-cell interactions and immunoglobulin E production 35, 36
  basophils and Th2 cell differentiation role 87, 88
  dendritic cell
    interactions 26–28
    polarization role 25, 26
  late-phase reactions 36, 37
  radiocontrast media hypersensitivity pathophysiology 164
  subsets
    Th1 29
    Th2 29, 30
    Th9 31
    Th17 30, 31
    Tregs 31–34
  Treg suppression of effector cells 34, 35
  Toll-like receptors, types and functions 24, 25
  Tryptase, anaphylaxis diagnosis 126, 127, 187

Vasopressin, anaphylaxis management 206